Acta Biotheoretica

, Volume 60, Issue 4, pp 333–356 | Cite as

Aggregation and Competitive Exclusion: Explaining the Coexistence of Human Papillomavirus Types and the Effectiveness of Limited Vaccine Conferred Cross-Immunity

Regular Article

Abstract

Human Papillomavirus (HPV) types are sexually transmitted infections that cause a number of human cancers. According to the competitive exclusion principle in ecology, HPV types that have lower transmission probabilities and shorter durations of infection should be outcompeted by more virulent types. This, however, is not the case, as numerous HPV types co-exist, some which are less transmissible and more easily cleared than others. This paper examines whether this exception to the competitive exclusion principle can be explained by the aggregation of infection with HPV types, which results in patchy spatial distributions of infection, and what implications this has for the effect of vaccination on multiple HPV types. A deterministic transmission model is presented that models the patchy distribution of infected individuals using Lloyd’s mean crowding. It is first shown that higher aggregation can result in a reduced capacity for onward transmission and reduce the required efficacy of vaccination. It is shown that greater patchiness in the distribution of lower prevalence HPV types permits co-existence. This affirms the hypothesis that the aggregation of HPV types provides an explanation for the violation of the competitive exclusion principle. Greater aggregation of lower prevalence types has important implications where type-specific HPV vaccines also offer cross-protection against non-target types. It is demonstrated that the degree of cross-protection can be less than the degree of vaccine protection conferred against directly targeted types and still result in the elimination of non-target types when these non-target types are patchily distributed.

Keywords

Human Papillomavirus vaccination Competitive exclusion Competitive coexistence Patchiness SIS model 

References

  1. Anderson RM, May RM (1991) Infectious diseases of humans: dynamics and control. Oxford University Press, OxfordGoogle Scholar
  2. Arima Y, Winer RL, Feng Q, Hughes JP, Lee SK, Stern ME, O’Reilly SF, Koutsky LA (2010) Development of genital warts after incident detection of human Papillomavirus infection in young men. J Inf Dis 202(8):1181–1184CrossRefGoogle Scholar
  3. Barlow ND (1991) A spatially aggregated disease/host model for bovine Tb in New Zealand possum populations. J Appl Ecol 28(3):777–793CrossRefGoogle Scholar
  4. Bliss CI, Owen ARG (1958) Negative binomial distributions with a common k. Biometrika 45(1/2):37–58CrossRefGoogle Scholar
  5. Bogaards J, Berkhof J, Coupe V, Xiridou M, Meijer C, Wallinga J, Berkhof J (2011) Long-term impact of human Papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence. Epidemiol Bull 22(4):505–515CrossRefGoogle Scholar
  6. Bremermann HJ, Thieme HR (1989) A competitive exclusion principle for pathogen virulence. J Math Biol 27(2):179–190CrossRefGoogle Scholar
  7. Brown DR, Kjaer SK, Sigurdsson K, Iversen O-E, Hernandez-Avila M et al (2009) The impact of quadrivalent human Papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J Inf Dis 199(7):926–935CrossRefGoogle Scholar
  8. Canfell K, Barnabas R, Patnick J, Beral V (2004) The predicted effect of changes in cervical screening practice in the UK: results from a modelling study. Br J Cancer 91(3):530–536CrossRefGoogle Scholar
  9. Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, Galloway DA (2000) Comparison of human Papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Inf Dis 181(6):1911–1919CrossRefGoogle Scholar
  10. Castillo-Chavez C, Huang W, Li J (1996) Competitive exclusion in Gonorrhea models and other sexually transmitted diseases. SIAM J Appl Math 56(2):494CrossRefGoogle Scholar
  11. Castillo-Chavez C, Huang W, Li J (1999) Competitive exclusion and coexistence of multiple strains in an SIS STD model. SIAM J Appl Math 59(5):1790–1811CrossRefGoogle Scholar
  12. Chaturvedi AK, Katki HA, Hildesheim A, Rodríguez AC, Quint W, Schiffman M, Van Doorn LJ, Porras C, Wacholder S, Gonzalez P, Sherman ME, Herrero R (2011) Human Papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease. J Inf Dis 203(7):910–920CrossRefGoogle Scholar
  13. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S (2003) Human Papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88:63–73CrossRefGoogle Scholar
  14. Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJF, Vaccarella S, Anh PTH et al (2005) Worldwide distribution of human Papillomavirus types in cytologically normal women in the international agency for research on cancer HPV prevalence surveys: a pooled analysis. Lancet 366(9490):991–998CrossRefGoogle Scholar
  15. de Visser RO, Smith AMA, Rissel CE, Richters J, Grulich AE (2003) Sex in Australia: Heterosexual experience and recent heterosexual encounters among a representative sample of adults. Aust NZ J Pub Health 27(2):146–154CrossRefGoogle Scholar
  16. De Vuyst H, Clifford G, Li N, S F (2009) HPV infection in Europe. Eur J Cancer 45(15):2632–2639CrossRefGoogle Scholar
  17. Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Ali H, Wand H, Fairley CK (2011) Quadrivalent human Papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Inf Dis 11(1):39–44CrossRefGoogle Scholar
  18. Du P, Lemkin A, Kluhsman B, Chen J, Roth R, MacEachren A, Meyers C, Zurlo J, Lengerich E (2010) The roles of social domains, behavioral risk, health care resources, and chlamydia in spatial clusters of US cervical cancer mortality: not all the clusters are the same. Cancer Cause Control 21(10):1669–1683CrossRefGoogle Scholar
  19. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, Markowitz LE (2007) Prevalence of HPV infection among females in the United States. J Am Med Assoc 297(8):813–819CrossRefGoogle Scholar
  20. Elbasha EH, Galvani AP (2005) Vaccination against multiple HPV types. Math Biosci 197(1):88–117CrossRefGoogle Scholar
  21. Fisher R (1941) The negative binomial distribution. Ann Eugenics 11:182–187Google Scholar
  22. Gertig DM, Brotherton JML, Saville AM (2011) Measuring human Papillomavirus (HPV) vaccination coverage and the role of the national HPV vaccination program register, Australia. Sex Health 8(2):171–178CrossRefGoogle Scholar
  23. Giuliano A, Lee JH, Fulp W, Villa L, Lazcano E, Papenfuss M, Abrahamsen M, Salmeron J, Anic G, Rollison D, Smith D (2011) Incidence and clearance of genital human Papillomavirus infection in men (HIM): a cohort study. Lancet 377(9769):932–940CrossRefGoogle Scholar
  24. Giuliano AR, Harris R, Sedjo RL, Baldwin S, Roe D, Papenfuss MR, Abrahamsen M, Inserra P, Olvera S, Hatch K (2002) Incidence, prevalence, and clearance of type-specific human Papillomavirus infections: the young wome’s health study. J Inf Dis 186(4):462CrossRefGoogle Scholar
  25. Giuliano AR, Lu B, Nielson CM, Flores R, Papenfuss MR, Lee JH, Abrahamsen M, Harris RB (2008) Age specific prevalence, incidence, and duration of human Papillomavirus infections in a cohort of 290 US men. J Inf Dis 198(6):827–835CrossRefGoogle Scholar
  26. Goldie S, Kohli M, Grima D, Franco EL, Weinstein MC, Bosch FX (2004) Projected clinical benefits and cost-effectiveness of a human Papillomavirus 16/18 vaccine. J Natl Cancer Inst 96(8):604–615CrossRefGoogle Scholar
  27. Goldie SJ, Grima D, Kohli M, Wright TC, Weinstein M, Franco E (2003) A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer 106(6):896–904CrossRefGoogle Scholar
  28. Hardin G (1960) The competitive exclusion principle. Sci Agric 131(3409):1292–1297CrossRefGoogle Scholar
  29. Hartley S, Shorrocks B (2002) A general framework for the aggregation model of coexistence. J Anim Ecol 71(4):651–662CrossRefGoogle Scholar
  30. Herrero R (2009) Human Papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types. J Inf Dis 199(7):919–922CrossRefGoogle Scholar
  31. Hilker FM, Langlais M, Petrovskii SV, Malchow H (2007) A diffusive SI model with Allee effect and application to FIV. Math Biosci 206(1):61–80CrossRefGoogle Scholar
  32. Ho GYF, Studentsov Y, Hall CB, Bierman R, Beardsley L, Lempa M, Burk RD (2002) Risk factors for subsequent cervicovaginal human Papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J Inf Dis 186(6):737–742CrossRefGoogle Scholar
  33. Hyman JM, Li J (1997) Behavior changes in SIS STD models with selective mixing. SIAM J Appl Math 57:1082–1094CrossRefGoogle Scholar
  34. Insinga R, Dasbach E, Elbasha E, Liaw KL, Barr E (2007) Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women. Infect Agent Cancer 2(1):15CrossRefGoogle Scholar
  35. Insinga RP, Dasbach EJ, Elbasha EH, Liaw KL, Barr E (2007) Incidence and duration of cervical human Papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives. Cancer Epidem Biomar 16(4):709–715CrossRefGoogle Scholar
  36. Iwao S (1968) A new regression method for analyzing the aggregation pattern of animal populations. Res Pop Ecol 10(1):1–20CrossRefGoogle Scholar
  37. Iwao S (1976) A note on the related concepts mean crowding and mean concentration. Res Pop Ecol 17(2):240–242CrossRefGoogle Scholar
  38. Iwao S, Kuno E (1968) Use of the regression of mean crowding on mean density for estimating sample size and the transformation of data for the analysis of variance. Res Pop Ecol 10(2):210–214CrossRefGoogle Scholar
  39. Keeling MJ (2000) Simple stochastic models and their power-law type behaviour. Theor Pop Biol 58(1):21–31CrossRefGoogle Scholar
  40. Keeling MJ, Rohani P (2008) Modelling infectious diseases in humans and animals. Princeton University Press, PrincetonGoogle Scholar
  41. Kulasingam S, Connelly L, Conway E, Hocking JS, Myers E, Regan DG, Roder D, Ross J, Wain G (2007) A cost-effectiveness analysis of adding a human Papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sex Health 4(3):165–175CrossRefGoogle Scholar
  42. Kuno E (1988) Aggregation pattern of individuals and the outcomes of competition within and between species: differential equation models. Res Pop Ecol 30(1):69–82CrossRefGoogle Scholar
  43. Lefevere E, Hens N, De Smet F, Van Damme P (2011) Dynamics of HPV vaccination initiation in Flanders (Belgium) 2007–2009: a Cox regression model. BMC Pub Health 11:470CrossRefGoogle Scholar
  44. Liaw KL, Hildesheim A, Burk RD, Gravitt P, Wacholder S, Manos MM, Scott DR, Sherman ME, Kurman RJ, Glass AG, Anderson SM, Schiffman M (2001) A prospective study of human Papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Inf Dis 183(1):8–15CrossRefGoogle Scholar
  45. Lloyd M (1967) Mean crowding. J Anim Ecol 36(1):1–30CrossRefGoogle Scholar
  46. Lloyd-Smith JO (2007) Maximum likelihood estimation of the negative binomial dispersion parameter for highly overdispersed data, with applications to infectious diseases. PLoS ONE 2(2):e180CrossRefGoogle Scholar
  47. Lu B, Hagensee ME, Lee JH et al (2010) Epidemiologic factors associated with seropositivity to human Papillomavirus type 16 and 18 virus? Like particles and risk of subsequent infection in men. Cancer Epidem Biomar 19(2):511–516CrossRefGoogle Scholar
  48. Lu B, Viscidi RP, Lee JH, Wu Y, Villa LL, Lazcano-Ponce E, da Silva C, J R, Baggio ML, Quiterio M, Salmerón J, Smith DC, Abrahamsen, Martha, Papenfuss M, Stockwell HG, Giuliano AR (2011) Human Papillomavirus (HPV) 6, 11, 16, and 18 seroprevalence is associated with sexual practice and age: results from the multinational HPV infection in men study (HIM study). Cancer Epidem Biomar 20(5):990–1002Google Scholar
  49. MacArthur R, Wilson E (1967) The theory of island biogeography. Princeton University Press, Princeton, NJ, USAGoogle Scholar
  50. Malik ZA, Hailpern SM, Burk RD (2009) Persistent antibodies to HPV virus-like particles following natural infection are protective against subsequent cervicovaginal infection with related and unrelated HPV. Vir Immunol 22(6):445–449CrossRefGoogle Scholar
  51. Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, Alvarez FB, Bautista OM, Jansen KU, Barr E, Investigators ftPoPS (2006) Efficacy of human Papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 107(1):18–27CrossRefGoogle Scholar
  52. May RM, Anderson RM (1987) Transmission dynamics of HIV infection. Nat Biotechnol 326(6109):137–142CrossRefGoogle Scholar
  53. Molano M, den Brule A, Plummer M, Weiderpass E, Posso H, Arslan A, Meijer CJ, Munoz N, Franceschi S (2003) Determinants of clearance of human Papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 158(5):486–494CrossRefGoogle Scholar
  54. Orozco-Colin A, Carrillo-Garcia A, Mendez-Tenorio A et al (2010) Geographical variation in human Papillomavirus prevalence in Mexican women with normal cytology. Int J Inf Dis 14(12):e1082–e1087CrossRefGoogle Scholar
  55. Paaso AE, Louvanto K, Syrjänen KJ, Waterboer T, Grénman SE, Pawlita M, Syrjänen SM (2011) Lack of type-specific concordance between human Papillomavirus (HPV) serology and HPV DNA detection in the uterine cervix and oral mucosa. J Gen Virol 92(9):2034–2046CrossRefGoogle Scholar
  56. Pielou E (1969) An introduction to mathematical ecology. Wiley Interscience, New York, NY, USAGoogle Scholar
  57. Plummer M, Vaccarella S, Franceschi S (2011) Multiple human Papillomavirus infections: the exception or the rule?. J Inf Dis 203(7):891–893CrossRefGoogle Scholar
  58. Regan D, Philp D, Waters E (2010) Unresolved questions concerning human Papillomavirus infection and transmission: a modelling perspective. Sex Health 7(3):368–375CrossRefGoogle Scholar
  59. Richardson H, Kelsall G, Tellier P, Voyer H, Abrahamowicz M, Ferenczy A, Coutlee F, Franco EL (2003) The natural history of type-specific human Papillomavirus infections in female university students. Cancer Epidemiol Biomar 12(6):485–490Google Scholar
  60. Sanders G, Taira A (2003) Cost effectiveness of a potential vaccine for Human Papillomavirus. Emerg Infect Dis 9(1):37–48CrossRefGoogle Scholar
  61. Schiffman M, Clifford G, Buonaguro F (2009) Classification of weakly carcinogenic human Papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer 4(1). doi:10.1186/1750-9378-4-8
  62. Shih-Yen C, Delius H, Halpern A, Bernard H (1995) Analysis of genomic sequences of 95 Papillomavirus types: uniting typing, phyolgeny and taxonomy. J Virol 69(5):3074–3083Google Scholar
  63. Skjeldestad FE, Mehta V, Sings HL et al (2008) Seroprevalence and genital DNA prevalence of HPV types 6, 11, 16 and 18 in a cohort of young Norwegian women: study design and cohort characteristics. Acta Obstet Gyn Scan 87(1):81–88CrossRefGoogle Scholar
  64. Solomon D, Davey D, Kurman R, Moriarty A, O’Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T, Young N et al (2002) The 2001 Bethesda system. J Am Med Assoc 287(16):2114–2119CrossRefGoogle Scholar
  65. Southwood TRE (1978) Ecological methods. 2nd edn. Chapman&Hall, LondonCrossRefGoogle Scholar
  66. Swinton J, Garnett GP, Brunham RC, Anderson RM (1992) Gonococcal infection, infertility, and population growth: I. Endemic states in behaviourally homogeneous growing populations. Math Med Biol 9(2):107–126CrossRefGoogle Scholar
  67. Sycuro LK, Xi F Long, Hughes JP, Feng Q, Winer RL, Lee SK, O’Reilly S, Kiviat NB, Koutsky LA (2008) Persistence of genital human Papillomavirus infection in a long-term follow-up study of female university students. J Inf Dis 198(7):971–978CrossRefGoogle Scholar
  68. Taira A, Neukermans C, Sanders G (2004) Evaluating human Papillomavirus vaccination programs. Emerg Infect Dis 10(11):1915–1923CrossRefGoogle Scholar
  69. The FUTURE II Study Group: (2007) Quadrivalent Vaccine against human Papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356(19):1915–1927CrossRefGoogle Scholar
  70. The FUTURE I/II Study Group (2010) Four year efficacy of prophylactic human Papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. Br Med J 341(jul20_1):c3493–Google Scholar
  71. Trottier H, Mahmud S, Prado JCM, Sobrinho JS, Costa MC, Rohan TE, Villa LL, Franco EL (2008) Type-specific duration of human Papillomavirus infection: implications for human Papillomavirus screening and vaccination. J Infect Dis 197(10):1436–1447CrossRefGoogle Scholar
  72. Trottier H, Ferreira S, Thomann P, Costa MC, Sobrinho JS, Prado JCM, Rohan TE, Villa LL, Franco EL (2010) Human Papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. Cancer Res 70(21):8569–8577CrossRefGoogle Scholar
  73. Vandepapeliere P, Barrasso R, Meijer CJLM, Walboomers JMM, Wettendorff M, Stanherry LR, Lacey CJN (2005) Randomized controlled trial of an adjuvanted human Papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination. J Inf Dis 192(12):2099–2107CrossRefGoogle Scholar
  74. Viscidi RP, Schiffman M, Hildesheim A (2004) Seroreactivity to human Papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidem Biomar 13:324–327CrossRefGoogle Scholar
  75. Wang Z (2009) Backward bifurcation in simple SIS model. Acta Math Sin 25(1):127–136CrossRefGoogle Scholar
  76. Winer RL, Kiviat NB, Hughes JP, Adam DE, Lee SK, Kuypers JM, Koutsky LA (2005) Development and duration of human Papillomavirus lesions, after initial infection. J Inf Dis 191(5):731–738CrossRefGoogle Scholar
  77. Winer RL, Hughes JP, Feng Q, Xi LF, Cherne S, O’Reilly S, Kiviat NB, Koutsky LA (2011) Early natural history of incident, type-specific human Papillomavirus infections in newly sexually active young women. Cancer Epidem Biomar 20(4):699–707CrossRefGoogle Scholar
  78. Yamamura K (1989) Effect of aggregation on the reproductive rate of populations. Res Pop Ecol 31(2):161–168CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  1. 1.The University of Notre Dame AustraliaBroadwayAustralia

Personalised recommendations